Publicaciones en colaboración con investigadores/as de Mayo Clinic (7)

2024

  1. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

    Frontiers in Neurology, Vol. 15

2023

  1. Ravulizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder

    Annals of Neurology, Vol. 93, Núm. 6, pp. 1053-1068

2022

  1. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

    Multiple Sclerosis Journal, Vol. 28, Núm. 3, pp. 480-486

  2. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456

2021

  1. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

    Multiple Sclerosis and Related Disorders, Vol. 47

  2. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD

    Annals of Neurology, Vol. 89, Núm. 6, pp. 1088-1098

2020

  1. Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis

    Frontiers in Pediatrics, Vol. 8